Peptide library / Immune & defense / Icotrokinra
Icotrokinra
An oral peptide that blocks the IL-23 receptor, developed for psoriasis.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Plaque psoriasisLarge trials
- Ulcerative colitisSmall human studies
How it is thought to work
Icotrokinra is a pill that blocks IL-23 signaling, the same pathway targeted by injected antibodies for psoriasis.
What the evidence shows
Phase 3 ICONIC trials reported clear skin in a large share of patients compared with placebo.
Safety and unknowns
Side effects were similar to placebo in trials so far.
Regulatory status
Submitted to the FDA. Check the FDA database for current status.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Immune & defense
LL-37
Wellness and performanceThe only cathelicidin in humans, an antimicrobial and wound-healing peptide produced by skin and immune cells.
LTX-315
In clinical trialsAn oncolytic peptide injected into tumors to trigger an immune attack.
Glatiramer acetate
FDA-approvedA random mixture of four amino acids used in relapsing multiple sclerosis.
General information, not medical advice. Do not buy or inject unregulated peptides.